Abstract 14991: The Angiogenesis Inhibitor of Bevacizumab Has a Direct Effect on Arterial Sclerosis
Purpose: Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, constitutes a well-established treatment in various type of cancers. Neovascularisation interferes with several pathophysiological processes in the myocardium and the vessels. This prospective study evaluated the impact of the specific angiogenesis inhibitor on the arterial sclerosis.
Methods: Twenty four patients diagnosed with metastatic breast or colorectal cancer were treated with combined chemotherapy including bevacizumab (n=12, bevacizumab group) or not (n=12, control group). The arterial sclerosis of the patients was estimated by carotid-femoral Pulse Wave Velocity (c-fPWV) at baseline, at the middle of the initiation of the therapy (12 weeks), at the end of the therapy (24 weeks) and at 6 months after the end of the therapy.
Results: Blood pressure values had no significant difference between measurements. Carotid- femoral Pulse Wave Velocity was positively related to therapy with bevacizumab in all phases of the follow-up. In bevacizumab group, c-fPWV was significantly higher at 12 weeks (9.16±2.32 versus 9.46±2.54 m/s, p=0.034), and at 24 weeks (9.16±2.32 versus 9.82±2.95 m/s, p=0.026) compared to baseline values. Furthermore, c-fPWV remained higher 6 months after the end of the therapy (9.16±2.32 versus 9.96±2.88 m/s, p=0.016). In control group, there was no significant difference between the measurements at 12 weeks of treatment (8.56±2.26 versus 8.41±2.10 m/s, p=0.296), at 24 weeks (8.56±2.26 versus 8.54±2.28 m/s, p=0.785), and at 6 months after the end of treatment (8.56±2.26 versus 8.48±2.23 m/s, p=0.482).
Conclusions: The angiogenesis inhibitor of bevacizumab has a direct effect on arterial sclerosis. Thus, neovasculirazation may play a role in the functional properties of peripheral arteries.
- © 2013 by American Heart Association, Inc.